AGL 38.40 Decreased By ▼ -1.18 (-2.98%)
AIRLINK 128.43 Decreased By ▼ -2.79 (-2.13%)
BOP 7.05 Increased By ▲ 0.24 (3.52%)
CNERGY 4.52 Decreased By ▼ -0.19 (-4.03%)
DCL 8.19 Decreased By ▼ -0.25 (-2.96%)
DFML 38.75 Decreased By ▼ -2.72 (-6.56%)
DGKC 78.76 Decreased By ▼ -3.33 (-4.06%)
FCCL 31.57 Decreased By ▼ -1.53 (-4.62%)
FFBL 70.98 Decreased By ▼ -1.89 (-2.59%)
FFL 12.13 Decreased By ▼ -0.13 (-1.06%)
HUBC 107.50 Decreased By ▼ -3.24 (-2.93%)
HUMNL 13.76 Decreased By ▼ -0.75 (-5.17%)
KEL 4.89 Decreased By ▼ -0.30 (-5.78%)
KOSM 7.23 Decreased By ▼ -0.38 (-4.99%)
MLCF 37.50 Decreased By ▼ -1.40 (-3.6%)
NBP 68.08 Increased By ▲ 4.07 (6.36%)
OGDC 186.00 Decreased By ▼ -6.82 (-3.54%)
PAEL 24.70 Decreased By ▼ -0.98 (-3.82%)
PIBTL 7.25 Decreased By ▼ -0.09 (-1.23%)
PPL 147.00 Decreased By ▼ -7.07 (-4.59%)
PRL 24.70 Decreased By ▼ -1.13 (-4.37%)
PTC 16.90 Decreased By ▼ -0.91 (-5.11%)
SEARL 79.21 Decreased By ▼ -3.09 (-3.75%)
TELE 7.38 Decreased By ▼ -0.38 (-4.9%)
TOMCL 32.50 Decreased By ▼ -0.96 (-2.87%)
TPLP 8.15 Decreased By ▼ -0.34 (-4%)
TREET 16.60 Decreased By ▼ -0.02 (-0.12%)
TRG 56.20 Decreased By ▼ -1.20 (-2.09%)
UNITY 27.80 Increased By ▲ 0.29 (1.05%)
WTL 1.32 Decreased By ▼ -0.05 (-3.65%)
BR100 10,301 Decreased By -203.1 (-1.93%)
BR30 30,327 Decreased By -899 (-2.88%)
KSE100 96,629 Decreased By -1450.3 (-1.48%)
KSE30 30,080 Decreased By -479.2 (-1.57%)

Bangladesh's leading drug maker Beximco Pharmaceuticals Limited (BPL) said on Saturday it has raised 6.5 million pounds through the issue of 8,175,750 further global depository receipts (GDRs) on the London Stock Exchange, each representing one ordinary share of 10 taka each at an issue price of 80 pence per GDR.
The newly issued GDRs were admitted for trading on June 1 on the Alternative Investment Market (AIM) of the London Stock Exchange, a BPL statement said.
"We have been delighted by the interest in Beximco from international investors since the company's IPO in London last year and we are grateful to them for their continuing support in this fundraising as we develop the infrastructure of our business and invest in its growth," said Nazmul Hassan, Chief Executive Officer of Beximco Pharmaceuticals said in the statement.

Copyright Reuters, 2006

Comments

Comments are closed.